

## Arbeiten aus der Klinik 2014 – IF 2014

Anzahl Publikationen: 194  
Davon IF-Arbeiten: 133  
Summe IF: 570.157

1. **Adorjan K, Kistner N, Fink S, Dehning S, Falkai P**  
Arbeitsfähigkeit und psychische Erkrankung.  
MMW Fortschr Med 2014; 156: 49-51. IF -
2. **Agarwal A, Zhang M, Trembak-Duff I, Unterbarnscheidt T, Radyushkin K, Dibaj P, Martins de Souza D, Boretius S, Brzózka MM, Steffens H, Berning S, Teng Z, Gummert MN, Tantra M, Guest PC, Willig KI, Frahm J, Hell SW, Bahn S, Rossner MJ, Nave KA, Ehrenreich H, Zhang W, Schwab MH**  
Dysregulated expression of neuregulin-1 by cortical pyramidal neurons disrupts synaptic plasticity.  
Cell Rep 2014; 8: 1130-45. IF 8.358
3. **Aichert D, Rüther T**  
Schwangerschaft & Tabakabhängigkeit. Diagnostik, Risiken, Rauchentwöhnung.  
gyne 2014; 15-21. IF -
4. **Aichmüller C, Soyka M**  
Evidenzbasierte Therapie des Alkoholentzugssyndroms.  
Suchtmed 2014; 16: 53-60. IF -
5. **Amorim M, Fernandes G, Oliveira P, Martins-de-Souza D, Dias-Neto E, Nunes D**  
The overexpression of a single oncogene (ERBB2/HER2) alters the proteomic landscape of extracellular vesicles.  
Proteomics 2014; 14: 1472-79. IF 3.807
6. **Apelt SM, Scherbaum N, Soyka M**  
Induction and switch to buprenorphine-naloxone in opioid dependence treatment: predictive value of the first four weeks.  
Heroin Addict Relat Clin Probl 2014; 16: 87-97. IF 0.643
7. **Badowska D, Schmitt A, Falkai P**  
Connectivity and cognition in neuropsychiatric disorders with special emphasis on Alzheimer's disease and Chorea Huntington.  
Eur Arch Psychiatry Clin Neurosci 2014; 264: 465-6. IF 3.525
8. **Baier PC, Brzózka MM, Shahmoradi A, Reinecke L, Kroos C, Wichert SP, Oster H, Wehr MC, Taneja R, Hirrlinger J, Rossner MJ**

Mice lacking the circadian modulators SHARP1 and SHARP2 display altered sleep and mixed state endophenotypes of psychiatric disorders. PLOS One 2014; 9: e110310. IF 3.234

9. **Bajbouj M, Padberg F**  
A perfect match: noninvasive brain stimulation and psychotherapy. Eur Arch Psychiatry Clin Neurosci 2014; 264 Suppl1: S27-33. IF 3.525
10. **Baker JH, Sisk CL, Thornton LM, Brandt H, Crawford S, Fichter MM, Halmi KA, Johnson C, Jones I, Kaplan AS, Mitchell JE, Strober M, Treasure J, Woodside DB, Berrettini WH, Kaye WH, Bulik CM, Klump KL**  
Primary amenorrhea in anorexia nervosa: impact on characteristic masculine and feminine traits. Eur Eat Disorders Rev 2014; 22: 32-8. IF 2.461
11. **Banzhaf-Strathmann J, Benito E, May S, Arzberger T, Tahirovic S, Kretschmar H, Fischer A, Edbauer D**  
MicroRNA-125b induces tau hyperphosphorylation and cognitive deficits in Alzheimer's disease. EMBO J 2014; 33: 1667-80. IF 10.434
12. **Batra A, Jähne A, Rüter T**  
Tabakabhängigkeit (ICD-10 F.17.2)  
In: Voderholzer U, Hohagen F (Hrsg.)  
Therapie psychischer Erkrankungen. State of the Art 2013 2014. Urban & Fischer, München, 2014, S. 63-72.
13. **Bauer M, Pfennig A, Severus E, Whybrow PC, Angst J, Möller H-J**  
Reply to the letter to the editor by George et al. World J Biol Psychiatry 2014; 15: 169-70. IF 4.183
14. **Baumgärtner J, Eckermann G, Grohmann R, Schmauß M, Toto S, Stübner S**  
Sedierung unter Kombinationsbehandlung – unerwünschte Arzneimittelwirkung als Aufnahmegrund. Psychopharmakotherapie 2014; 21: 118-22. IF -
15. **Baumgärtner G, Soyka M**  
Alkoholabhängigkeit – Risikofaktoren, Diagnostik und Therapie. Genusstrinker oder krank? MMW Fortschr Med 2014; 156 Sonderheft 2: 65-72. IF -
16. **Baumgärtner G, Soyka M**  
Diagnostik alkoholbezogener Störungen. Psychiatrie & Neurologie 2014: 12-16. IF -
17. **Berger M, Musil R, Seemüller F**  
Phasenprophylaxe bipolarer Erkrankungen. Fortschr Neurol Psychiatr 2014; 82: 346-360. IF 0.629

18. **Biesemann C, Gronborg M, Luquet E, Wichert SP, Bernard V, Bungers SR, Cooper B, Varoqueaux F, Li L, Byrne JA, Urlaub H, Jahn O, Brose N, Herzog E**  
Proteomic screening of glutamatergic mouse brain synaptosomes isolated by fluorescence activated sorting.  
EMBO J 2014; 334: 157-70. IF 10.434
19. **Born C, Amann BL, Grunze H, Post RM, Schärer L**  
Saving time and money: a validation of the self ratings on the prospective NIMH life-chart method (NIMH-LCM).  
BMC Psychiatry 2014; 14: 130. IF 2.210
20. **Boutros NN, Gallinat J, Pogarell O**  
Isolated epileptiform discharges in psychiatric patients: to treat or not to treat.  
J Clin Neurophysiol 2014; 31: 395. IF 1.429
21. **Boutros NN, Kiollos SB, Pogarell O, Gallinat J**  
Predictive value of isolated epileptiform discharges for a favorable therapeutic response to antiepileptic drugs in nonepileptic psychiatric patients.  
J Clin Neurophysiol 2014; 31: 21-30. IF 1.429
22. **Brunnauer A, Buschert V, Laux G**  
Demenz und Autofahren.  
Nervenarzt 2014; 85: 811-815. IF 0.787
23. **Brunnauer A, Widder B, Laux G**  
Grundlagen der Fahreignungsbeurteilung bei neurologischen und psychischen Erkrankungen.  
Nervenarzt 2014; 85: 805-810. IF 0.787
24. **Bunse T, Wobrock T, Strube W, Padberg F, Palm U, Falkai P, Hasan A**  
Motor cortical excitability assessed by transcranial magnetic stimulation in psychiatric disorders: a systematic review.  
Brain Stimul 2014; 7: 158-69. IF 4.399
25. **Café-Mendes CC, Ferro ES, Britto LRG, Martins-de-Souza D**  
Using mass spectrometry-based peptidomics to understand the brain and disorders such as parkinson's disease and schizophrenia.  
Curr Top Med Chem 2014; 14: 369-81. IF 3.420
26. **Café-Mendes C, Gattaz WF, Schmitt A, Britto LRG, Martins-de-Souza D**  
Proteomic characterization of the brain and cerebrospinal fluid of schizophrenia patients.  
In: Martins-de-Souza D (ed)  
Proteomics and Metabolomics in Psychiatry.  
Adv Biol Psychiatry. Karger, Basel 2014, S. 1-15.

27. **Campanella S, Pogarell O, Boutrous N**  
Event-related potentials in substance use disorders: a narrative review based on articles from 1984 to 2012.  
Clin EEG Neurosci 2014; 45: 67-76. IF 2.219
28. **Clarke TK, Crist RC, Doyle GA, Weiss AR, Brandt H, Crawford S, Crow S, Fichter MM, Halmi KA, Johnson C, Kaplan AS, La Via M, Mitchell JE, Strober M, Rotondo A, Treasure J, Woodside DB, Keel P, Klump KL, Lilenfeld L, Plotnicov K, Magistretti PJ, Bergen AW, Kaye WH, Schork NJ, Berrettini WH**  
Characterization of genetic variation in the VGLL4 gene in anorexia nervosa.  
Psychiatr Genet 2014; 24: 183-4. IF 1.941
29. **Consortium on Lithium Genetics, Hou L, Heilbronner U, Rietschel M, Kato T, Kuo PH, McMahon FJ, Schulze TG (et al. 109 contributors Falkai P)**  
Variant GADL1 and response to lithium in bipolar I disorder.  
N Engl J Med 2014; 370: 1855-60. IF 55.873
30. **Cording C, Nedopil N**  
Zivilrechtliche Begutachtungen. Ein Handbuch für die Praxis.  
Pabst, Lengerich, 2014.
31. **Corves C, Engel RR, Davis J, Leucht S**  
Do patients with paranoid and disorganized schizophrenia respond differently to antipsychotic drugs?  
Acta Psychiatr Scand 2014; 130: 40-5. IF 5.605
32. **Dabbert D, Mauer A, Fuchs T, Grohmann R, Toto S, Rütger E, Degner D**  
Makulopapulöses Exanthem als allergische Reaktion auf Quetiapin.  
Psychopharmakotherapie 2014; 21: 72-4. IF -
33. **Dean B, Möller H-J, Svensson TH, Geyer MA, Rujescu D, Scarr E, Millan MJ**  
Problems and solutions to filling the drying drug pipeline for psychiatric disorders: a report from the inaugural 2012 CINP Think Tank.  
Int J Neuropsychopharmacol 2014; 17: 137-148. IF 4.009
34. **Dehning S, Leitner B, Schennach R, Müller N, Bötzel K, Obermeier M, Mehrkens JH**  
Functional outcome and quality of life in Tourette's syndrome after deep brain stimulation of the posteroventrolateral globus pallidus internus: long-term follow-up.  
World J Biol Psychiatry. 2014; 15: 66-75. IF 4.183

35. **Dehning S, Reiß E, Krause D, Gasperi S, Meyer S, Dargel S, Müller N, Siebeck M**  
Empathy in high-tech and high-touch medicine.  
Patient Educ Couns 2014; 95: 259-264. IF 2.199
36. **Dejene S, Negash A, Tesfay K, Jobst A, Abera M**  
Depression and diabetes in Jimma University Specialized Hospital,  
Southwest Ethiopia.  
J Psychiatry 2014; 17: 3. IF -
37. **Dunn E, Felthous AR, Gagné P, Harding T, Kaliski, Kramp P, Lindqvist P, Nedopil N, Ogloff JRP, Skipworth J, Taylor PJ, Thomson L, Yoshikawa K**  
Forensic psychiatry and its interfaces outside the UK and Ireland.  
In: Gunn J, Taylor PJ (ed).  
Forensic Psychiatry. CRCPress Taylor and Francis Group 2014, S. 111-47.
38. **Eser-Valeri D**  
Psychopharmakotherapie somatoformer Störungen.  
Die Psychiatrie 2014; 11: 189-196.
39. **Falkai P**  
Herausforderungen durch den demographischen Wandel – psychische Erkrankungen heute und morgen.  
Fortschr Neurol Psychiatr 2014; 82: 615. IF 0.629
40. **Falkai P**  
Kraepelins Erbe.  
In: Löhrs U, Neupert W, Peter K, Sattler S, Sittner G (Hrsg)  
Forschen – heilen – lehren. Die Medizin an der Ludwig-Maximilians-Universität München, DVA, 2014. S. 305-8.
41. **Falkai P, Reich-Erkelenz D, Schmitt A**  
Von der Pathophysiologie zur Entwicklung von Leitlinien und neuen Behandlungskonzepten der Schizophrenie.  
Fortschr Neurol Psychiatr 2014; 82: 186-190. IF 0.629
42. **Falkai P, Schmitt A**  
Lifestyle verändert Körper und Geist.  
MMW Fortschr Med 2014; 156: 36. IF -
43. **Falkai P, Schmitt A**  
Verbesserung kognitiver Defizite als Ziel neuer Behandlungsansätze bei der Schizophrenie.  
Fortschr Neurol Psychiatr 2014; 82: 127. IF 0.629
44. **Farias AS, Pradella F, Schmitt A, Santos LMB, Martins-de-Souza D**  
Ten years of proteomics in multiple sclerosis.  
Proteomics 2014; 14: 467-480. IF 3.807

45. **Fichter MM, Quadflieg N, Lindner S**  
Rückfallprophylaxe auf Internetbasis bei Anorexia nervosa – längerfristiger Verlauf in einer „Intent-to-treat“-Stichprobe.  
Z Psychiatr Psychol Psychother 2014; 62: 35-42. IF 0.500
46. **Focke NK, Trost S, Paulus W, Falkai P, Gruber O**  
Do manual and voxel-based morphometry measure the same? A proof of concept study.  
Front Psychiatry 2014; 5: 39. IF -
47. **Fountoulakis KN, Möller H-J**  
Are antidepressants clinically useful? Conclusion of a decade of debate.  
World Psychiatry 2014; 13: 201-202. IF 14.225
48. **Gaebel W, Falkai P**  
Psychiatrie in Europa.  
Die Psychiatrie 2014; 11: 3-4. IF -
49. **Gaebel W, Falkai P**  
The European Psychiatric Association: Mission, Structure and Perspectives.  
Die Psychiatrie 2014; 11: 5-9. IF -
50. **Gaebel W, Riesbeck M, Wölwer W, Klinke A, Eickhoff M, von Wilmsdorff M, Heuser I, Maier W, Klosterkötter J, Falkai P, Schlösser R, Schmitt A, Riedel M, Klingberg S, Köpcke W, Ohmann C, Möller H-J**  
Rates and predictors of remission in first-episode schizophrenia within 1 year of antipsychotic maintenance treatment. Results of a randomized controlled trial within the German Research Network on Schizophrenia.  
Schizophr Res 2014; 152: 478-86. IF 3.923
51. **Gelernter J, Kranzler HR, Sherva R, Almasy L, Koesterer R, Smith AH, Anton R, Preuss UW, Ridinger M, Rujescu D, Wodarz N, Zill P, Zhao H, Farrer LA**  
Genome-wide association study of alcohol dependence: significant findings in African- and European-Americans including novel risk loci.  
Mol Psychiatry 2014; 19: 41-49. IF 14.496
52. **George MS, Schlaepfer T, Padberg F, Fitzgerald PB**  
Brain stimulation treatments for depression.  
World J Biol Psychiatry 2014; 15: 167-8. IF 4.183
53. **Girma E, Möller-Leimkühler AM, Dehning S, Müller N, Tesfaye M, Froeschl G**  
Self-stigma among caregivers of people with mental illness: toward caregivers' empowerment.  
J Multidiscip Healthc 2014; 7; 37-43. IF -

54. **Girma E, Möller-Leimkühler AM, Müller N, Dehning S, Froeschl G, Tesfaye M**  
Public stigma against family members of people with mental illness: findings from the Gilgel Gibe Field Research Center (GGFRC), Southwest Ethiopia.  
BMC Int Health Hum Rights 2014; 14: 2. IF 1.366
55. **Götzl JK, Mori K, Damme M, Fellerer K, Tahirovic S, Kleinberger G, Janssens J, van der Zee J, Lang CM, Kremmer E, Martin JJ, Engelborghs S, Kretzschmar HA, Arzberger T, van Broeckhoven C, Haass C, Capell A**  
Common pathobiochemical hallmarks of progranulin-associated frontotemporal lobar degeneration and neuronal ceroid lipofuscinosis.  
Acta Neuropathol 2014; 127: 845-60. IF 10.762
56. **Grohmann R, Engel RR, Möller H-J, Rüter E, van der Velden JW, Stübner S**  
Flupentixol use and adverse reactions in comparison with other common first- and second-generation antipsychotics: data from the AMSP study.  
Eur Arch Psychiatry Clin Neurosci 2014; 264: 131-141. IF 3.525
57. **Grüber L, Falkai P, Hasan A**  
Depression bei Schizophrenie.  
Psych up2date, 2014; 8: 365-76. IF -
58. **Grunze H, Soyka M**  
Pharmakotherapie komorbider schizophrener und bipolarer Psychosen bei Substanzabhängigkeit.  
Suchtmed 2014; 16: 61-67. IF -
59. **Haddad PM, Fleischhacker WW, Peuskens J, Cavallaro R, Lean ME, Morozova M, Reynolds G, Azorin JM, Thomas P, Möller H-J**  
SMARTS (Systematic monitoring of adverse events related to treatmentS): The development of a pragmatic patient-completed checklist to assess antipsychotic drug side effects.  
Ther Adv Psychopharmacol 2014; 4: 15-21 IF -
60. **Haeckert J, Bunse T, Wirth S, Hamerle M, Falkai P, Hasan A**  
Massive, previously undetected cancer metastasis revealed by application of a depot antipsychotic: a care report.  
J Clin Psychiatry 2014; 75: e705-06. IF 5.498
61. **Häßler F, Kinze W, Nedopil N**  
Praxishandbuch Forensische Psychiatrie.  
Medizinisch Wissenschaftliche Verlagsgesellschaft, Berlin, 2014.
62. **Hasan A, Falkai P, Scherk H**  
Schizophrenie, schizotype und wahnhaftige Störungen.  
In: Kasper S, Volz HP (Hrsg) Psychiatrie und Psychotherapie compact. Thieme, Stuttgart, 2014, S. 118-135.

63. **Hasan A, Gruber O**  
Untersuchung kortikaler Plastizität mit repetitiver transkranieller Magnetstimulation und transkranieller Gleichstromstimulation.  
In: Gruber O, Falkai P (Hrsg.)  
Systemische Neurowissenschaften in der Psychiatrie. Methoden und Anwendung in der Praxis.  
Kohlhammer, Stuttgart, 2014, S. 208-223.
64. **Hasan A, Hertel N, Falkai P**  
Verwirrheitszustände. Der schizophrene Formenkreis ist ungeahnt groß.  
MMW Fortschr Med 2014; 156: 34. IF -
65. **Hasan A, Malchow B, Falkai P, Schmitt A**  
Die Glutamathypothese der Schizophrenie.  
Fortschr Neurol Psychiatr 2014; 82: 447-456. IF 0.629
66. **Hasan A, Schmitt A, Falkai P**  
Psychotische Symptome (Wahn und Halluzinationen).  
In: Pantel, Schröder, Sieber, Kruse (eds)  
Praxishandbuch der Altersmedizin. Geriatrie Gerontopsychiatrie Gerontologie. Kohlhammer, Stuttgart, 2014, S. 380-394.
67. **Hasan A, Strube W**  
Wegweiser für die Therapieentscheidung.  
Clinicum neuropsych 2014: 8-11. IF -
68. **Hasan A, Wobrock T**  
Transkranielle Magnetstimulation (TMS).  
In: Gruber O, Falkai P (Hrsg.)  
Systemische Neurowissenschaften in der Psychiatrie. Methoden und Anwendung in der Praxis.  
Kohlhammer, Stuttgart, 2014, S. 189-207.
69. **Hertel N, Falkai P, Hasan A**  
„Ich sehe Lichtblitze und höre Stimmen“.  
MMW Fortschr Med 2014; 156: 38-40. IF 2013 –
70. **Jähne A, Rütger T, Deest H, Gehrig H, de Zeeuw J, Alberti A, Mulzer K**  
Evaluierung eines strukturierten Tabakentwöhnungsprogramms für die ärztliche Praxis.  
Dtsch Med Wochenschr 2014; 139: 127-33. IF 0.542
71. **Jobst A, Albert A, Bauriedl-Schmidt C, Mauer MC, Renneberg B, Buchheim A, Sabaß L, Falkai P, Zill P, Padberg F**  
Social exclusion leads to divergent changes of oxytocin levels in borderline patients and healthy subjects.  
Psychother Psychosom 2014; 83: 252-254. IF 9.196



72. **Jobst A, Dehning S, Ruf S, Notz T, Buchheim A, Henning-Fast K, Meißner D, Meyer S, Bondy B, Müller N, Zill P**  
Oxytocin and vasopressin levels are decreased in the plasma of male schizophrenia patients.  
Acta Neuropsychiatrica 2014; 26: 347-55. IF 0.802
73. **Jobst A, Padberg F, Buchheim A**  
Interpersonelle Probleme und das Oxytocin-System bei der Borderline-Störung.  
Persönlichkeitsstörungen 2014; 18: 167-76. IF -
74. **Jobst A, Sabaß L, Falkai P, Padberg F**  
Komplexe affektive Erkrankungen – eine klinische Herausforderung.  
Die Psychiatrie 2014; 11: 197-202.
75. **Kambeitz J, Koutsouleris N**  
Neuroimaging in der Psychiatrie. Multivariate Analysetechniken zur Diagnostik und Verlaufsprädiktion.  
Nervenarzt 2014; 85: 714-719. IF 0.787
76. **Kambeitz J, Romanos M, Ettinger U**  
Meta-analysis of the association between dopamine transporter genotype and response to methylphenidate treatment in ADHD.  
Pharmacogenomics J 2014; 14: 77-84. IF 4.229
77. **Karch S, Hegerl U, Pogarell O**  
Elektroenzephalographie.  
In: Gruber O, Falkai P (Hrsg.)  
Systemische Neurowissenschaften in der Psychiatrie. Methoden und Anwendung in der Praxis.  
Kohlhammer, Stuttgart, 2014, S.153-176.
78. **Karch S, Pogarell O**  
Exzessiver PC-/Internetkonsum: kann die Neurobiologie zur Klassifikation beitragen?  
Sucht 2014; 60: 360-61. IF -
79. **Karch S, Voelker JM, Thalmeier T, Ertl M, Leicht G, Pogarell O, Mulert C**  
Deficits during voluntary selection in adult patients with ADHD: new insights from single-trial coupling of simultaneous EEG/fMRI.  
Front Psychiatry 2014; 5: 1-10. IF -
80. **Kasper S, Gastpar M, Müller WE, Volz HP, Möller H-J, Schläpke S, Diemel A**  
Lavender oil preparation Silexan is effective in generalized anxiety disorder – a randomized, double-blind comparison to placebo and paroxetine.  
Int J Neuropsychopharmacol 2014; 17: 859-69. IF 4.009

81. **Kirchner S, Falkai P, Hasan A**  
Adhärenz als Schlüssel zum Erfolg.  
Clinicum neuropsych 2014; 30-32. IF -
82. **Koch S, Quadflieg N, Fichter M**  
Purging disorder: a pathway to death? A review of 11 cases.  
Eat Weight Disord 2014; 19: 21-9. IF 0.785
83. **Koller G**  
Commentary on Holland et al. (2014): Opioid maintenance treatment--  
how much supervision is helpful?  
Addiction 2014; 109: 608-9. IF 4.738
84. **Koutsouleris N, Davatzikos C, Borgwardt S, Gaser Ch, Bottlender R,  
Frodl T, Falkai, Riecher-Rössler A, Möller H-J, Reiser M, Pantelis C,  
Meisenzahl E**  
Accelerated brain aging in schizophrenia and beyond: a  
neuroanatomical marker of psychiatric disorders.  
Schizophr Bull 2014; 40: 1140-1153. IF 8.450
85. **Krause D, Jobst A, Kirchberg F, Kieper S, Härtl K, Kästner R, Myint  
A-M, Müller N, Schwarz MJ**  
Prenatal immunologic predictors of postpartum depressive symptoms:  
a prospective study for potential diagnostic markers.  
Eur Arch Psychiatry Clin Neurosci 2014; 264: 615-624. IF 3.525
86. **Küfner H, Melia M, Soyka M**  
Manualized psychosocial treatment versus standard care in opioid  
maintenance treatment: results of a randomized clinical trial and  
follow-up study.  
J Psychosoc Rehabil Ment Health 2014; 1: 61-75. IF -
87. **Kühn KU, Wiedemann K, Hellweg R, Möller H-J**  
Stellenwert von Depotformulierungen in der Langzeittherapie der  
Schizophrenie.  
Fortschr Neurol Psychiatr 2014; 82: 557-565. IF 0.629
88. **Laux GH, Brunnauer A**  
Fahrtauglichkeit bei affektiven Störungen und unter Psychopharmaka.  
Nervenarzt 2014; 85: 822-828. IF 0.787
89. **Lefaucheur JP, André-Obadia N, Antal A, Ayache SS, Baeken C,  
Benninger DH, Cantello RM, Cincotta M, de Carvalho M, De Ridder  
D, Devanne H, Di Lazzaro V, Filipović SR, Hummel FC, Jääskeläinen  
SK, Kimiskidis VK, Koch G, Langguth B, Nyffeler T, Oliviero A,  
Padberg F, Poulet E, Rossi S, Rossini PM, Rothwell JC, Schönfeldt-  
Lecuona C, Siebner HR, Slotema CW, Stagg CJ, Valls-Sole J,  
Ziemann U, Paulus W, Garcia-Larrea L**  
Evidence-based guidelines on the treatment use of repetitive  
transcranial magnetic stimulation (rTMS).  
Clin Neurophysiol 2014; 125: 2150-2206. IF 3.097

90. **Lennertz L, Wagner M, Grabe HJ, Franke PE, Guttenthaler V, Rampacher F, Schulze-Rauschenbach S, Vogeley A, Benninghoff J, Ruhrmann S, Pukrop P, Klosterkötter J, Falkai P, Maier W, Mössner R**  
5-HT<sub>3</sub> receptor influences the washing phenotype and visual organization in obsessive-compulsive disorder supporting 5-HT<sub>3</sub> receptor antagonists as novel treatment option.  
Eur Neuropsychopharmacol 2014; 24: 86-94. IF 4.369
91. **Lieb M, Palm U, Meyer S, Sarubin N, Mokhtari-Nejad R, Riedel M, Möller H-J, Seemüller F**  
Risikofaktoren für Suizide und Suizidversuche an einem Universitätsklinikum.  
Psychiatr Prax 2014; 41: 195-199. IF 1.821
92. **Lindner SE, Fichter MM, Quadflieg N**  
Set-shifting and its relation to clinical and personality variables in full recovery of anorexia nervosa.  
Eur Eat Disord Rev 2014; 22: 252-9. IF 2.461
93. **Maccarrone G, Lebar M, Martins-de-Souza D**  
Brain quantitative proteomics combining GeLC-MS and isotope-codes protein labeling (ICPL).  
In: Martins-de-Souza D (ed)  
Shotgun Proteomics: Methods and Protocols.  
Methods in Molecular Biology Vol. 1156, 2014.  
Springer Science+Business Media New York 2014, S. 175-185.
94. **Maier W, Falkai P, Schmitt A**  
Selected issues of the DGPPN Congress in 2013.  
Eur Arch Psychiatry Clin Neurosci 2014; 264 Suppl 1: S1-S2. IF3.525
95. **Malchow B, Schmitt A, Falkai P**  
Sport tut auch der Psyche gut!  
MMW Fortschr Med 2014; 156: 41-3. IF -
96. **Mannert K, Dehning S, Krause D, Leitner B, Rieder G, Siebeck M, Tesfaye M, Abero M, Hailesilassie H, Tesfay K, Jobst A**  
Quality of life in Ethiopia's street youth at a rehabilitation center and the association with trauma.  
J Traumatic Stress 2014; 27: 593-601. IF 2.360
97. **Martins-de-Souza D (ed)**  
Proteomics and Metabolomics in Psychiatry.  
Adv Biol Psychiatry. Karger, Basel 2014
98. **Martins-de-Souza D**  
Proteomics, metabolomics, and protein interactomics in the characterization of the molecular features of major depressive

disorder.  
Dialogues Clin Neurosci 2014; 16: 63-73. IF -

99. **Martins-de-Souza D (ed)**  
Shotgun Proteomics: Methods and Protocols.  
Methods in Molecular Biology Vol. 1156, 2014.  
Springer Science+Business Media New York 2014.
100. **Martins-de-Souza D, Carvalho PC, Schmitt A, Junqueira M, Nogueira FC, Turch CW, Domont GB**  
Deciphering the human brain proteome: characterization of the anterior temporal lobe and corpus callosum as part of the Chromosome 15-centric Human Proteome Project.  
J Proteome Res 2014; 13: 147-57. IF 4.245
101. **Martins-de-Souza D, Maccarrone G, Ising M, Kloiber S, Lucae S, Holsboer F, Turck CW**  
Blood mononuclear cell proteome suggests integrin and ras signaling as critical pathways for antidepressants treatment response.  
Biol Psychiatry 2014; 76: e15-7. IF 10.255
102. **Martins-de-Souza D, Maccarrone G, Ising M, Kloiber S, Lucae S, Holsboer F, Turck CW**  
Plasma fibrinogen: now also an antidepressant response marker?  
Transl Psychiatry 2014; 4: e352. IF 5.620
103. **May S, Hornburg D, Schludi MH, Arzberger T, Rentzsch K, Schwenk BM, Grässer FA, Mori K, Kremmer E, Banzhaf-Strathmann J, Mann M, Meissner F, Edbauer D**  
C9orf72 FTL/ALS-associated Gly-Ala dipeptide repeat proteins cause neuronal toxicity and Unc119 sequestration.  
Acta Neuropathol 2014; 128: 485-503. IF 10.762
104. **Mayer S, van der Gaag RJ, Dom G, Wassermann D, Gaebel W, Falkai P, Schüle C**  
European Psychiatric Association (EPA) guidance on post-graduate psychiatric training in Europe.  
Eur Psychiatry 2014; 29: 101-6. IF 3.439
105. **McGrath LM, Yu D, Marshall C, Davis LK, Thiruvahindrapuram B, Li B, Cappi C, Gerber G, Wolf A, Schroeder FA, Osiecki L, O'Dushlaine C, Kirby A, Illmann C, Haddad S, Gallagher P, Fagerness JA, Barr CL, Bellodi L, Benarroch F, Bienvenu OJ, Black DW, Bloch MH, Bruun RD, Budman CL, Camarena B, Cath DC, Cavallini MC, Chouinard S, Coric V, Cullen B, Delorme R, Denys D, Derks EM, Dion Y, Rosário MC, Eapen V, Evans P, Falkai P, Fernandez TV, Garrido H, Geller D, Grabe HJ, Grados MA, Greenberg BD, Gross-Tsur V, Grünblatt E, Heiman GA, Hemmings SM, Herrera LD, Hounie AG, Jankovic J, Kennedy JL, King RA, Kurlan R, Lanzagorta N, Leboyer M, Leckman JF, Lennertz L, Lochner C, Lowe TL, Lyon GJ, Macciardi F, Maier W, McCracken JT, McMahon W, Murphy DL,**

**Naarden AL, Neale BM, Nurmi E, Pakstis AJ, Pato MT, Pato CN, Piacentini J, Pittenger C, Pollak Y, Reus VI, Richter MA, Riddle M, Robertson MM, Rosenberg D, Rouleau GA, Ruhrmann S, Sampaio AS, Samuels J, Sandor P, Sheppard B, Singer HS, Smit JH, Stein DJ, Tischfield JA, Vallada H, Veenstra-VanderWeele J, Walitza S, Wang Y, Wendland JR, Shugart YY, Miguel EC, Nicolini H, Oostra BA, Moessner R, Wagner M, Ruiz-Linares A, Heutink P, Nestadt G, Freimer N, Petryshen T, Posthuma D, Jenike MA, Cox NJ, Hanna GL, Brentani H, Scherer SW, Arnold PD, Stewart SE, Mathews CA, Knowles JA, Cook EH, Pauls DL, Wang K, Scharf JM**

Copy number variation in obsessive-compulsive disorder and Tourette Syndrome: a cross-disorder study.

J Am Acad Child Adolesc Psychiatry 2014; 53: 910-919. IF 7.260

106. **Melcher T, Wolter S, Falck S, Wild E, Wild F, Gruber E, Falkai P, Gruber O**  
Common and disease-specific dysfunctions of brain systems underlying attentional and executive control in schizophrenia and bipolar disorder.  
Eur Arch Psychiatry Clin Neurosci 2014; 264: 517-32. IF 3.525
107. **Michl P, Meindl T, Meister F, Born C, Engel RR, Reiser M, Hennig-Fast K**  
Neurobiological underpinnings of shame and guilt: a pilot fMRI study.  
Soc Cogn Affect Neurosci 2014; 9: 150-7. IF 7.372
108. **Mobascher A, Bohus M, Dahmen N, Dietl L, Giegling I, Jungkunz M, Kleindienst N, Limberger M, Meisenzahl E, Rietschel M, Roepke S, Schmahl C, Schott B, Schwarze CE, Tadic A, Treutlein J, Vogel F, Witt SH, Zetzsche T, Rujescu D, Lieb K**  
Association between dopa decarboxylase gene variants and borderline personality disorder.  
Psychiatry Res 2014; 219: 693-5. IF 2.467
109. **Möller H-J**  
Do features of Mozart's letter-writing style indicate the presence of a neuropsychiatric disorder? Controversies about the Bäsle letters.  
Eur Arch Psychiatry Clin Neurosci 2014; 264: 367-77. IF 3.525
110. **Möller H-J**  
The consequences of DSM-5 for psychiatric diagnosis and psychopharmacotherapy.  
Int J Psychiatry Clin Pract 2014; 18: 78-85. IF 1.391
111. **Möller H-J, Seemüller F, Schennach-Wolff R, Stübner S, Rüter E, Grohmann R**  
History, background, concepts and current use of comedication and polypharmacy in psychiatry.  
Int J Neuropsychopharmacol 2014; 17: 983-96. IF 4.009

112. **Müller JL, Neodpil N**  
Forensic Neuroscience – useful technique or a new source of misunderstanding?  
Monatsschr Kriminol 2014; 97: 356-64. IF 0.136
113. **Müller N**  
Immunology of major depression.  
Neuroimmunomodulation 2014; 21: 123-130. IF 1.882
114. **Müller N, Krause D, Weidinger E, Schwarz M**  
Immunologische Behandlungsoptionen bei schizophrenen Störungen.  
Fortschr Neurol Psychiatr 2014; 82: 210-219. IF 0.629
115. **Müller S, Costa A, Keeser D, Pogarell O, Berman A, Coates U, Reiser MF, Riedel M, Möller H-J, Ettinger U, Meindl T**  
The effects of methylphenidate on whole brain intrinsic functional connectivity.  
Hum Brain Mapp 2014; 35: 5379-88. IF 5.969
116. **Müller-Isberner R, Eucker S, von Hecker B, Nedopil N**  
Therapie im Maßregelvollzug.  
In: Voderholzer U, Hohagen F (Hrsg.)  
Therapie psychischer Erkrankungen. State of the Art 2013 2014.  
Urban & Fischer, München, 2014, S. 421-435.
117. **Nedopil N**  
Gekränkte Eitelkeiten – Terroristische Einzelkämpfer.  
Forensische Psychiatrie, Psychologie und Kriminologie 2014; 8: 246-253. IF -
118. **Nedopil N**  
Sexualstraftaten im Erwachsenenalter.  
In: Häßler F, Kinze W, Nedopil N. Praxishandbuch Forensische Psychiatrie. Medizinische Wissenschaftliche Verlagsgesellschaft, Berlin, 2014, S. 165-178.
119. **Nedopil N**  
Zum Streit um die Verurteilung von Anders Breivik: Schuldfähigkeit als Zweckmäßigkeitkategorie.  
In: Pollähne H, Lange-Jobst C. Verbrechen, Rechtfertigungen, Wahnsysteme. Lit-verlag, Berlin, 2014, S. 31-46.
120. **Nischalke HD, Lutz P, Krämer B, Söhne J, Müller T, Rosendahl J, Fischer J, Berg T, Hittatiya K, Fischer H-P, Soyka M, Semmo N, Nattermann J, Sauerbruch T, Strassburg CP, Stickel F, Spengler U**  
A common polymorphism in the NCAN gene is associated with hepatocellular carcinoma in alcoholic liver disease.  
J Hepathol 2014; 61: 1073-79. IF 11.336
121. **Nothdurfter C, Schmotz C, Sarubin N, Baghai TC, Laenger A, Lieb M, Bondy B, Rupprecht R, Schüle D**

Effects of escitalopram/quetiapine combination therapy versus escitalopram monotherapy on hypothalamic-pituitary-adrenal-axis activity in relation to antidepressant effectiveness.  
J Psychiatr Res 2014; 52: 15-20. IF 3.957

122. **Nowak D, Jörres RA, Rüter T**  
E-Cigarettes – prevention, pulmonary health, and addiction.  
Dtsch Arztebl Int 2014; 111: 349-55. IF 3.518
123. **O'Donoghue T, Morris DW, Fahey C, Da Costa A, Moore S, Cummings E, Leicht G, Karch S, Hoerold D, Tropea D, Foxe JJ, Gill M, Corvin A, Donohoe G**  
Effects of ZNF804A on auditory P300 response in schizophrenia.  
Transl Psychiatry 2014; 4: e345. IF 5.620
124. **Oertel-Knöchel V, Mehler P, Thiel C, Steinbrecher K, Malchow B, Tesky V, Ademmer K, Prvulovic D, Banzer W, Zopf Y, Schmitt A, Hänsel F**  
Effects of aerobic exercise on cognitive performance and individual psychopathology in depressive and schizophrenia patients.  
Eur Arch Psychiatry Clin Neurosci 2014; 264: 589-604. IF 3.525
125. **Oliveira BM, Coorsen JR, Martins-de-Souza D**  
2DE: The phoenix of proteomics.  
J Proteomics 2014; 104: 140-150. IF 3.807
126. **Oppek K, Koller G, Zwergal A, Pogarell O**  
Intravenous administration and abuse of bupropion: a case report and a review of the literature.  
J Addict Med 2014; 8: 290-3. IF 1.756
127. **Palm U, Ayache SS, Padberg F, Lefaucheur JP**  
Non-invasive brain stimulation therapy in multiple sclerosis: a review of tDCS, rTMS and ECT results.  
Brain Stimul 2014; 7: 849-54. IF 4.399
128. **Palm U, Feichtner KB, Hasan A, Gauglitz G, Langguth B, Nitsche MA, Keeser D, Padberg F**  
The role of contact media at the skin-electrode interface during transcranial direct current stimulation (tDCS).  
Brain Stimul 2014; 7: 762-4. IF 4.399
129. **Palm U, Hasan A, Dehning S, Keeser D, Hummel I, Falkai P, Padberg F**  
Bifrontale transkranielle Gleichstromstimulation zur Behandlung der Schizophrenie.  
Nervenheilkunde 2014; 33: 382-386. IF -
130. **Palm U, Thasler WE, Rittler P, Epple AN, Lieb M, Mokhtari-Nejad R, Rospleszcz S, de la Fontaine L, Segmiller FM, Eser-Valeri D**  
Screening for psychiatric disorders in bariatric surgery candidates with

the german version of the Patient Health Questionnaire.  
Advances in Psychiatry 2014; ID 165818. IF -

131. **Quednow BB, Brzózka MM, Rossner MJ**  
Transcription factor 4 (TCF4) and schizophrenia: integrating the animal and the human perspective.  
Cell Mol Life Sci 2014; 71: 2815-35. IF 5.808
132. **Radenbach K, Falkai P, Weber-Reich T, Simon A**  
Joint crisis plans and psychiatric advance directives in German psychiatric practice.  
J Med Ethics 2014; 40: 343-5. IF 1.511
133. **Reich-Erkelenz D, Schmitt A, Falkai P**  
New aspects of cognition domains and psychopathological measures in psychiatry.  
Eur Arch Psychiatry Clin Neurosci 2014; 264: 647-9. IF 3.525
134. **Rüther T**  
E-Zigarette: Tabak- oder medizinisches Produkt? Pro und Contra aus therapeutischer Perspektive.  
Sucht 2014; 60: 345-49. IF -
135. **Rüther T**  
Tabak.  
In: Angerer, Glaser, Letzel, Nowak, Gündel, Henningsen, Lahmann (Hrsg.)  
Psychische und psychosomatische Gesundheit in der Arbeit.  
ecomed Medizin, Heidelberg, 2014, S. 424-429.
136. **Rüther T, Bobes J, de Hert M, Svensson TH, Mann K, Batra A, Gorwood P, Möller H-J**  
EPA Guidance on tobacco dependence and strategies for smoking cessation in people with mental illness.  
Eur Psychiatry 2014; 29: 65-82. IF 3.439
137. **Rüther T, Eberhardt K, Kiss A, Pogarell O**  
Reduziertes Rauchen: Was können Interventionen erreichen und wie sollten sie gestaltet sein?  
Suchttherapie 2014; 15: 179-86. IF 0.159
138. **Samara MT, Engel RR, Millier A, Kandenwein J, Toumi M, Leucht S**  
Equipercentile linking of scales measuring functioning and symptoms: examining the GAF, SOFAS, CGI-S, and PANSS  
Eur Neuropsychopharmacol 2014; 24: 1767-1772. IF 4.369
139. **Sarubin N, Nothdurfter C, Schüle C, Lieb M, Uhr M, Born C, Zimmermann R, Bühner M, Konopka K, Rupprecht R, Baghai TC**  
The influence of Hatha Yoga as an add-on treatment in major depression on hypothalamic-pituitary-adrenal-axis activity: a



randomized trial.  
J Psychiatr Res 2014; 53: 76-83. IF 3.957

140. **Sarubin N, Nothdurfter C, Schmotz C, Wimmer A-M, Trummer J, Lieb M, Uhr M, Baghai TC, Wetter TC, Bühner M, Rupprecht R, Schüle C**  
Impact on cortisol and antidepressant efficacy of quetiapine and excitalopram in depression.  
Psychoneuroendocrinology 2014; 39: 141-151. IF 4.944
141. **Schicho W, Pogarell O**  
Neuropathophysiological Aspekte der Borderline-Persönlichkeitsstörung.  
Persönlichkeitsstörungen 2014; 18: 147-56. IF -
142. **Schicho W, Pogarell O**  
Physiological Aberrations in Panic Disorder.  
Curr Top Behav Neurosci 2014; 21: 185-95. IF -
143. **Schlegl S, Quadflieg N, Löwe B, Cuntz U, Voderholzer U**  
Specialized inpatient treatment of adult anorexia nervosa: effectiveness and clinical significance of changes.  
BMC Psychiatry 2014; 14: 258. IF 2.210
144. **Schmitt A, Falkai P**  
Comorbidity, stigma and emotional perception in psychiatric disorders.  
Eur Arch Psychiatry Clin Neurosci 2014; 264: 1-2. IF 3.525
145. **Schmitt A, Falkai P**  
Historical aspects of Mozart's mental health and diagnostic insights of ADHD and personality disorders.  
Eur Arch Psychiatry Clin Neurosci 2014; 264: 363-5. IF 3.525
146. **Schmitt A, Falkai P**  
Reward, memory and prediction of treatment response in affective disorders.  
Eur Arch Psychiatry Clin Neurosci 2014; 264: 185-6. IF 3.525
147. **Schmitt A, Falkai P**  
Suicide ideation, stability of symptoms and effects of aerobic exercise in major depression.  
Eur Arch Psychiatry Clin Neurosci 2014; 264: 555-6. IF 3.525
148. **Schmitt A, Falkai P**  
The neuropathology of schizophrenia: new insights from postmortem studies.  
Eur Arch Psychiatry Clin Neurosci 2014; 264: 269-70. IF 3.525
149. **Schmitt A, Falkai P**  
The new risk variant CACNA1C and brain circuits in schizophrenia.  
Eur Arch Psychiatry Clin Neurosci 2014; 264: 91-2. IF 3.525

150. **Schmitt A, Malchow B, Hasan A, Falkai P**  
The impact of environmental factors in severe psychiatric disorders.  
Front Neurosci 2014; 8: 19. IF 3.656
151. **Schüle C**  
Chronische Depression – epidemiologische Daten und therapeutische  
Möglichkeiten.  
Fortschr Neurol Psychiatr 2014; 82: 155-173. IF 0.629
152. **Schüle C, Nothdurfter C, Rupprecht R**  
The role of allopregnanolone in depression and anxiety.  
Progress in Neurobiology 2014; 113: 79-87. IF 9.992
153. **Seemüller F, Godemann F, Wiegand HF, Wolff-Menzler C, Nitschke  
R, Häfner S, Pogarell O, Falkai P, Löhr M**  
Psychiatrische und medizinische Komorbiditäten bei Betroffenen mit  
bipolar affektiver Störung. Analyse auf Basis der VIPP-Datenbank.  
Nervenheilkunde 2014; 33: 865-872. IF -
154. **Seemüller F, Meier S, Obermeier M, Musil R, Bauer M, Adli M,  
Kronmüller K, Holsboer F, Brieger P, Laux G, Bender W, Heuser I,  
Zeiler J, Gaebel W, Riedel M, Falkai P, Möller H-J**  
Three-year long-term outcome of 458 naturalistically treated inpatients  
with major depressive episode: severe relapse rates and risk factors.  
Eur Arch Psychiatry Clin Neurosci 2014; 264: 567-75. IF 3.525
155. **Sellmann C, Villarin Pildain L, Schmitt A, Leonardi-Essmann F,  
Durrenberger PF, Spanagel R, Arzberger T, Kretzschmar H, Zink M,  
Gruber O, Herrera-Marschitz M, Reynolds R, Falkai P, Gebicke-  
Haerter PJ, Matthäus F**  
Gene expression in superior temporal cortex of schizophrenia patients.  
Eur Arch Psychiatry Clin Neurosci 2014; 264: 297-309. IF 3.525
156. **Soyka M**  
Affektive und Angststörungen und komorbide Suchterkrankungen.  
In: Walter M, Gouzoulis-Mayfrank (Hrsg.)  
Psychische Störungen und Suchterkrankungen.  
Kohlhammer, Stuttgart, 2014, S. 88-104.
157. **Soyka M**  
Alkohol- und Drogenabusus und Delinquenz.  
MschrKrim 2014; 97: 523-533. IF 2013 0.136
158. **Soyka M**  
Buprenorphine/Buprenorphine-naloxone treatment in opioid  
dependence and risk of peripheral oedema: Mini-review.  
Heroin Addict Relat Clin Probl 2014; 16: 31-36. IF 0.643

159. **Soyka M**  
Buprenorphine use and risk of abuse and diversion.  
Adv Pharmacoepidemiol Drug Saf 2014; 3: 145. IF -
160. **Soyka M**  
Nalmefen. Eine neue pharmakotherapeutische Option bei  
Alkoholabhängigkeit.  
Nervenarzt 2014; 85: 578-582. IF 0.787
161. **Soyka M**  
Nalmefene for the treatment of alcohol dependence: a current update.  
Int J Neuropsychopharmacol 2014; 17: 675-684. IF 4.009
162. **Soyka M**  
Neurobiology of aggression: neuroimaging findings.  
In: Dierckx RAJO, Otte A, de Vries EFJ, van Waarde A (eds)  
PET and SPECT in Psychiatry.  
Springer, Berlin Heidelberg 2014, S. 675-687.
163. **Soyka M**  
Opioids and traffic safety – focus on buprenorphine.  
Pharmacopsychiatry 2014; 47: 7-17. IF 1.851
164. **Soyka M**  
Psychotische Störungen durch Alkohol – eine eigene diagnostische  
Entität?  
Nervenarzt 2014; 85: 1093-1098. IF 0.787
165. **Soyka M**  
Suchtmittelkonsum bei Depression und Angsterkrankungen.  
SuchtMagazin 2014; 40: 11-14.
166. **Soyka M, Apelt S, Scherbaum N**  
Induction and switch to buprenorphine-naloxone in opioid dependence  
treatment: predictive value of the first four weeks.  
Heroin Addict Relat Clin Probl 2014; 16: 87-97. IF 0.643
167. **Soyka M, Backmund M, Schmidt P, Apelt S**  
Buprenorphine-Naloxone treatment in opioid dependence and risk of  
liver enzyme elevation: results from a 12-month observational study.  
Am J Addict 2014; 23: 563-569. IF 1.929
168. **Soyka A, Batra A**  
Benzodiazepinabhängigkeit (ICD-10 F.13.2).  
In: Voderholzer U, Hohagen F (Hrsg.)  
Therapie psychischer Erkrankungen. State of the Art 2013 2014.  
Urban & Fischer, München, 2014, S. 55-62.
169. **Soyka M, Dittert S, Kagerer-Volk S, Soyka M**  
Fahrtauglichkeit bei Abhängigkeitserkrankungen und Schizophrenie.  
Nervenarzt 2014; 85: 816-821. IF 0.787

170. **Soyka M, Hillemacher T**  
Commentary on Hser et al. (2014): to retain or not to retain-open questions in opioid maintenance therapy.  
Addiction 2014; 109: 88-9. IF 4.738
171. **Spellmann I, Rujescu D, Musil R, Giegling I, Genius J, Zill P, Dehning S, Cerovecki A, Seemüller F, Schennach R, Hartmann AM, Schäfer M, Müller N, Möller H-J, Riedel M**  
Pleckstrin homology domain containing 6 protein (PLEKHA6) polymorphisms are associated with psychopathology and response to treatment in schizophrenic patients  
Prog Neuropsychopharmacol Biol Psychiatry 2014; 51: 190-195. IF 3.689
172. **Steiner J, Schmitt A, Schroeter ML, Bogerts B, Falkai P, Turck CW, Martins-de-Souza D**  
S100B is downregulated in the nuclear proteome of schizophrenia corpus callosum.  
Eur Arch Psychiatry Clin Neurosci 2014; 264: 311-6. IF 3.525
173. **Stelzmann V, Haenisch F, Chan MK, Cooper JD, Steiner J, Steeb H, Martins-de-Souza D, Rahmoune H, Guest PC, Bahn S**  
Proteomic changes in serum of first onset, antidepressants drug-naive major depression patients.  
Int J Neuropsychopharmacol 2014; 17: 1599-608. IF 4.009
174. **Strube W, Hasan A, Bogner JR**  
[Organic psychoses in HIV-infected patients – an interdisciplinary case report].  
MMW Fortschr Med 2014; 156 Suppl 1: 22-3. IF -
175. **Strube W, Wobrock T, Bunse T, Palm U, Padberg F, Malchow B, Falkai P, Hasan A**  
Impairments in motor-cortical inhibitory networks across recent-onset and chronic schizophrenia: a cross-sectional TMS Study.  
Behav Brain Res. 2014; 264: 17-25. IF 3.028
176. **Synofzik M, Born C, Rominger A, Lummel N, Schöls L, Biskup S, Schüle C, Grasshoff U, Klopstock T, Adamczyk C**  
Targeted high-throughput sequencing identifies a TARDBP mutation as a cause of early-onset FTD without motor neuron disease.  
Neurobiol Aging 2014; 35: 1212.e1-1212.e5. IF 5.013
177. **Tardy M, Dold M, Engel RR, Leucht S**  
Flupenthixol versus low-potency first-generation antipsychotic drugs for schizophrenia.  
Cochrane Database Syst Rev 2014; 9: CD009227. IF 6.032
178. **Tardy M, Dold M, Engel RR, Leucht S**  
Trifluoperazine versus low-potency first-generation antipsychotic

drugs for schizophrenia.  
Cochrane Database Syst Rev 2014; 7: CD009396. IF 6.032

179. **Tardy M, Huhn M, Engel RR, Leucht S**  
Fluphenazine versus low-potency first-generation antipsychotic drugs for schizophrenia.  
Cochrane Database Syst Rev 2014; 8: CD 009230. IF 6.032
180. **Tardy M, Huhn M, Engel RR, Leucht S**  
Perphenazine versus low-potency first-generation antipsychotic drugs for schizophrenia.  
Cochrane Database Syst Rev 2014; 10: CD009369. IF 6.032
181. **Tardy M, Huhn M, Kissling W, Engel RR, Leucht S**  
Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia.  
Cochrane Database Syst Rev 2014; 7: CD009268. IF 6.032
182. **Thompson PM, Stein JL, Medland SE, Hibar DP, Vasquez AA, Renteria ME, Toro R, Jahanshad N, Schumann G, Franke B, Wright MJ, Martin NG, Agartz I, Alda M, Alhusaini S, Almasy L, Almeida J, Alpert K, Andreasen NC, Andreassen OA, Apostolova LG, Appel K, Armstrong NJ, Aribisala B, Bastin ME, Bauer M, Bearden CE, Bergmann O, Binder EB, Blangero J, Bockholt HJ, Bøen E, Bois C, Boomsma DI, Booth T, Bowman IJ, Bralten J, Brouwer RM, Brunner HG, Brohawn DG, Buckner RL, Buitelaar J, Bulayeva K, Bustillo JR, Calhoun VD, Cannon DM, Cantor RM, Carless MA, Caseras X, Cavalleri GL, Chakravarty MM, Chang KD, Ching CR, Christoforou A, Cichon S, Clark VP, Conrod P, Coppola G, Crespo-Facorro B, Curran JE, Czisch M, Deary IJ, de Geus EJ, den Braber A, Delvecchio G, Depondt C, de Haan L, de Zubicaray GI, Dima D, Dimitrova R, Djurovic S, Dong H, Donohoe G, Duggirala R, Dyer TD, Ehrlich S, Ekman CJ, Elvsåshagen T, Emsell L, Erk S, Espeseth T, Fagerness J, Fears S, Fedko I, Fernández G, Fisher SE, Foroud T, Fox PT, Francks C, Frangou S, Frey EM, Frodl T, Frouin V, Garavan H, Giddaluru S, Glahn DC, Godlewska B, Goldstein RZ, Gollub RL, Grabe HJ, Grimm O, Gruber O, Guadalupe T, Gur RE, Gur RC, Göring HH, Hagenaars S, Hajek T, Hall GB, Hall J, Hardy J, Hartman CA, Hass J, Hatton SN, Haukvik UK, Hegenscheid K, Heinz A, Hickie IB, Ho BC, Hoehn D, Hoekstra PJ, Hollinshead M, Holmes AJ, Homuth G, Hoogman M, Hong LE, Hosten N, Hottenga JJ, Hulshoff Pol HE, Hwang KS, Jack CR Jr, Jenkinson M, Johnston C, Jönsson EG, Kahn RS, Kasperaviciute D, Kelly S, Kim S, Kochunov P, Koenders L, Krämer B, Kwok JB, Lagopoulos J, Laje G, Landen M, Landman BA, Lauriello J, Lawrie SM, Lee PH, Le Hellard S, Lemaître H, Leonardo CD, Li CS, Liberg B, Liewald DC, Liu X, Lopez LM, Loth E, Lourdasamy A, Luciano M, Macciardi F,**

Machielsen MW, Macqueen GM, Malt UF, Mandl R, Manoach DS, Martinot JL, Matarin M, Mather KA, Mattheisen M, Mattingsdal M, Meyer-Lindenberg A, McDonald C, McIntosh AM, McMahon FJ, McMahon KL, Meisenzahl E, Melle I, Milaneschi Y, Mohnke S, Montgomery GW, Morris DW, Moses EK, Mueller BA, Muñoz Maniega S, Mühleisen TW, Müller-Myhsok B, Mwangi B, Nauck M, Nho K, Nichols TE, Nilsson LG, Nugent AC, Nyberg L, Olvera RL, Oosterlaan J, Ophoff RA, Pandolfo M, Papalampropoulou-Tsiridou M, Pappmeyer M, Paus T, Pausova Z, Pearlson GD, Penninx BW, Peterson CP, Pfennig A, Phillips M, Pike GB, Poline JB, Potkin SG, Pütz B, Ramasamy A, Rasmussen J, Rietschel M, Rijpkema M, Risacher SL, Roffman JL, Roiz-Santiañez R, Romanczuk-Seiferth N, Rose EJ, Royle NA, Rujescu D, Ryten M, Sachdev PS, Salami A, Satterthwaite TD, Savitz J, Saykin AJ, Scanlon C, Schmaal L, Schnack HG, Schork AJ, Schulz SC, Schür R, Seidman L, Shen L, Shoemaker JM, Simmons A, Sisodiya SM, Smith C, Smoller JW, Soares JC, Sponheim SR, Sprooten E, Starr JM, Steen VM, Strakowski S, Strike L, Sussmann J, Sämann PG, Teumer A, Toga AW, Tordesillas-Gutierrez D, Trabzuni D, Trost S, Turner J, Van den Heuvel M, van der Wee NJ, van Eijk K, van Erp TG, van Haren NE, van 't Ent D, van Tol MJ, Valdés Hernández MC, Veltman DJ, Versace A, Völzke H, Walker R, Walter H, Wang L, Wardlaw JM, Weale ME, Weiner MW, Wen W, Westlye LT, Whalley HC, Whelan CD, White T, Winkler AM, Wittfeld K, Woldehawariat G, Wolf C, Zilles D, Zwiers MP, Thalamuthu A, Schofield PR, Freimer NB, Lawrence NS, Drevets W; Alzheimer's Disease Neuroimaging Initiative, EPIGEN Consortium, IMAGEN Consortium, Saguenay Youth Study (SYS) Group.

The ENIGMA Consortium: large-scale collaborative analyses of neuroimaging and genetic data.

Brain Imaging Behav 2014; 8: 153-82. IF 4.598

183. **Tognin S, Riecher-Rössler A, Meisenzahl EM, Wood SJ, Hutton C, Borgwardt SJ, Koutsouleris N, Yung AR, Allen P, Phillips LJ, McGorry PD, Valli I, Velakoulis D, Nelson B, Woolley J, Pantelis C, McGuire P, Mechelli A**

Reduced parahippocampal cortical thickness in subjects at ultra-high risk for psychosis.

Psychol Med 2014; 44: 489-98. IF 5.938

184. **Trost S, Diekhof EK, Zvonik K, Lewandowski M, Usher J, Keil M, Zilles D, Falkai P, Dechent P, Gruber O**

Disturbed anterior prefrontal control of the mesolimbic reward system and increased impulsivity in bipolar disorder.

Neuropsychopharmacology 2014; 39: 1914-23. IF 7.048

185. **Von Wilmsdorff M, Bouvier ML, Henning U, Schmitt A, Schneider-Axmann T, Gaebel W**  
Sex-dependent metabolic alterations of rat liver after 12-week exposition to haloperidol or clozapine.  
Horm Metab Res 2014; 46: 782-788. IF 2.121
186. **Weidinger E, Krause D, Wildenauer A, Meyer S, Gruber R, Schwarz MJ, Müller N**  
Impaired activation of the innate immune response to bacterial challenge in Tourette syndrome.  
World J Biol Psychiatry. 2014 Aug;15: 453-8. IF 4.183
187. **Wennmann DO, Schmitz J, Wehr MC, Krahn MP, Koschmal N, Gromnitza S, Schulze U, Weide T, Chekuri A, Skryabin BV, Gerke V, Pavenstädt H, Duning K, Kremerskothen J**  
Evolutionary and molecular facts link the WWC protein family to hippo signaling.  
Mol Biol Evol 2014; 31: 1710-23. IF 9.105
188. **Wolf C, Mohr H, Schneider-Axmann T, Reif A, Wobrock T, Scherk H, Kraft S, Schmitt A, Falkai P, Gruber O**  
CACNA1C genotype explains interindividual differences in amygdala volume among patients with schizophrenia.  
Eur Arch Psychiatry Clin Neurosci 2014; 264: 93-102. IF 3.525
189. **Wolff-Menzler C, Maier B, Junne F, Löhr M, Große C, Falkai P, Pollmächer T, Salize HJ, Nitschke R, Hauth I, Deister A, Godemann F**  
Versorgungsindikatoren in der Psychiatrie und Psychosomatik (VIPP) – Ein Datenbank-Projekt.  
Fortschr Neurol Psychiatr 2014; 82: 394-400. IF 0.629
190. **Yilmaz Z, Kaplan AS, Tiwari AK, Levitan RD, Piran S, Bergen AW, Kaye WH, Hakonarson H, Wang K, Berrettini WH, Brandt HA, Bulik CM, Crawford S, Crow S, Fichter MM, Halmi KA, Johnson CL, Keel PK, Klump KL, Magistretti P, Mitchell JE, Strober M, Thornton LM, Treasure J, Woodside DB, Knight J, Kennedy JL**  
The role of leptin, melanocortin, and neurotrophin system genes on body weight in anorexia nervosa and bulimia nervosa.  
J Psychiatr Res 2014; 55: 77-86. IF 3.957
191. **Zink M, Englisch S, Schmitt A**  
Antipsychotic treatment modulates glutamate transport and NMDA receptor expression.  
Eur Arch Psychiatry Clin Neurosci 2014; 264 Suppl 1: S67-S82. IF 3.525
192. **Zink M, Schirmbeck F, Rausch F, Eifler S, Elkin H, Solojenkina X, Englisch S, Wagner M, Maier W, Lautenschlager M, Heinz A, Gudlowski Y, Janssen B, Gaebel W, Michel TM, Schneider F,**

**Lambert M, Naber D, Juckel G, Krueger-Oezguerdal S, Wobrock T, Hasan A, Riedel M, Müller H, Klosterkötter J, Bechdorf A**  
Obsessive-compulsive symptoms in at-risk mental states for psychosis: associations with clinical impairment and cognitive function.  
Acta Psychiatr Scand 2014; 130: 214-26. IF 5.605

193. **Zohar J, Nutt DJ, Kupfer DJ, Möller H-J, Yamawaki S, Spedding M, Stahl SS**  
A proposal for an updated neuropsychopharmacological nomenclature.  
Eur Neuropsychopharmacol 2014; 24: 1005-14. IF 4.369
194. **Zohles K, Andreae D, Grohmann R, Kropp S**  
Harninkontinenz unter dem selektiven Serotonin-Wiederaufnahmehemmer Sertralin.  
Psychopharmakotherapie 2014; 21: 283-4. IF -